RecruitingPhase 2NCT07225374
Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC
Studying Upper tract urothelial carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Samsung Medical Center
- Principal Investigator
- SE HOON PARK, MD,PhDSamsungMedicalCenter
- Intervention
- Avelumab 10 mg/kg(drug)
- Enrollment
- 48 target
- Eligibility
- 20 years · All sexes
- Timeline
- 2025 – 2029
Study locations (1)
- Samsung Medical Center, Seoul, Gangnam, South Korea
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07225374 on ClinicalTrials.govOther trials for Upper tract urothelial carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07452432Korean Prospective Upper Tract Urothelial Carcinoma CohortSamsung Medical Center
- RECRUITINGNANCT07321210Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma (T-LND UTUC): A Randomized Clinical TrialTianjin Medical University Second Hospital
- RECRUITINGPHASE2NCT07265947Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial CarcinomaTyra Biosciences, Inc
- ACTIVE NOT RECRUITINGPHASE2NCT07492225Neoadjuvant Chemotherapy Before Surgery vs Surgery Alone for UTUC: A Randomized TrialChanghai Hospital
- RECRUITINGPHASE2NCT06356155Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial CancerUniversity of Michigan Rogel Cancer Center
- RECRUITINGPHASE2NCT07126119Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUCTianjin Medical University Second Hospital
- RECRUITINGPHASE1NCT06848868Ambulatory Flexible URS for UTUC SurveillanceChinese University of Hong Kong
- RECRUITINGPHASE1, PHASE2NCT06668493Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal PelvisFerring Pharmaceuticals